Panels

Health Policy Panel

Impact of Health Care Reform: Industry Response

Key questions to be addressed:
  • What are the key aspects of reform that you would be most interested in seeing in the pending legislation?
  • What aspects or reimbursement, like bundled payments, will impact your business model and how will you adapt?
  • Given the planned coverage for the uninsured, what are the challenges you foresee to your firm?
  • How can you provide and utilize additional data on your services or products to deliver the most value to patients and consumers?
Panelists:
  • John (Jack) Bailey, Senior Vice President of Private, Public & Institutional Customers, GlaxoSmithKline
  • Benjamin Breier, Executive Vice President & Hospital Division President, Kindred Healthcare
  • Charles Cutler, Independent Consultant, Cutler Healthcare Consulting
  • Jon Kaplan, Partner & Managing Director, The Boston Consulting Group
  • Vadim Lubarsky, Director, Marwood Group

Pharma/Biotech Panel

What is the Next Business Model for the Pharma/Biotech Industry?

Key questions to be addressed:
  • Given the drop in patented assets over the next few years, what strategic bets should firms make as to research (activities before proven efficacy) vs. development (activities after proven efficacy)?
  • Is there a role for blockbuster drugs in the future business model of the pharma/biotech industry?
  • How are emerging markets influencing your decision making in research and later stage development?
Panelists:
  • Bill Anderson, Immunology & Ophthalmology Senior Vice President, Genentech
  • Gary J. Kurtzman, Vice President & Managing Director in Life Sciences, Safeguard
  • David Levy, Partner, Booz & Company
  • C. David Nicolson, Senior Vice President of Worldwide Licensing & Knowledge Management, Merck & Co.
  • Joshua Smiley, Vice President, CFO & LRL, Eli Lilly & Company
  • Adam Woodrow, VP of Inflammation, Pfizer

Medical Devices Panel

Medical Device Models for Delivering Exceptional Value

Key questions to be addressed:
  • How do you communicate the value of devices to providers, payers and patients?
  • Are there ways to better rationalize costs to provide greater accessibility to devices?
  • Can device combinations with pharma and IT offer novel methods for improving patient outcomes?
  • How might health care reform provide opportunities and present challenges to device firms?
Panelists:
  • Tom Hodson, Principal in the Life Sciences Industry, Deloitte Consulting LLP
  • Jack Kelley III, Director of Strategic Marketing & Business Development in Pharmaceutical Systems, BD
  • Suzanne McMonigle, Vice President of Marketing, Animas Corporation
  • Brent Melancon, Vice President of Healthcare Systems, Medtronic
  • David Nichols, Vice President of Product Development in Spine Division, Synthes

Finance Panel

Lessons Learned for the New Challenges Ahead

Key questions to be addressed:
  • How could you have positioned yourself to take advantage of the opportunities in the last year? Has this changed as you look ahead to the next year?
  • With the still sensitive market, what are the best methods for exit and how might these issues have changed your initial investment strategy?
  • How did you incorporate health care reform in your investment decisions and how likely do you see implementation affecting your portfolio?
  • A retrospective on the last three years: will things return to normal or are the fundamentals of the business truly different?
Panelists:
  • Umber Ahmed, Partner, Platinum Gate Capital Management LLC
  • Ron Eastman, Managing Director, Essex Woodlands Health Ventures
  • James Forbes, Head Global Principal Investments, Bank of America
  • Devin O’Reilly, Principal, Bain Capital
  • Robert Schrepfer, Managing Director, Healthcare Value Capital
  • Matthew P. Young, Managing Director, Global Healthcare Investment Banking, Barclays Capital

Venture Capital Panel

Life Science Venture Capital Investment Strategies in a Time of Reform

Key questions to be addressed:
  • Which sectors and types of companies currently have investors’ attention and are receiving funding today?
  • Given the valuation squeeze on investors, are VCs turning to alternative business models to adjust to the new environment?
  • The genomics revolution was a major catalyst for life science VC. What is the next big thing that could pull health care venture capital out of the doldrums?
  • From a deal-making perspective, what does a looming industry restructuring mean for life science venture capital?
Panelists:
  • Darren Black, Partner, SV Life Sciences
  • Brenda D. Gavin, Founding Partner, Quaker BioVentures
  • Roger Longman, Former Managing Director, Elsevier Business Intelligence / Windhover Information
  • Anupendra Sharma, Investment Partner, Siemens Venture Capital
  • Steven St. Peter, Partner, MPM Capital
[ Go to Speakers >> ]

Platinum Sponsor: Gold Sponsors: